Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation".
Saved in:
| Title: | Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation". |
|---|---|
| Authors: | Durrani K; a Division of Ophthalmology , University of Connecticut Health , Farmington , Connecticut , USA., Kempen JH; b Department of Ophthalmology , Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA.; c Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.; d Discovery Eye Center , MyungSung Christian Medical Center and MyungSung Medical School , Addis Ababa , Ethiopia., Foster CS; c Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.; e Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.; f Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA. |
| Corporate Authors: | Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group |
| Source: | Ocular immunology and inflammation [Ocul Immunol Inflamm] 2019; Vol. 27 (1), pp. 71. Date of Electronic Publication: 2017 Oct 18. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-5078 (Electronic) Linking ISSN: 09273948 NLM ISO Abbreviation: Ocul Immunol Inflamm Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-5078 |
|---|---|
| DOI: | 10.1080/09273948.2017.1379545 |
